CA
VTGN icon

Corrado Advisors’s VistaGen Therapeutics VTGN Stock Holding History

Corrado Advisors’s Portfolio VTGN Stock Details VTGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q3 		– Sell
-1,514
Closed -$62K – 105
2018
Q2 		$62K Sell
1,514
-700
-32% -$24.3K 0.04% 106
2018
Q1 		$62K Buy
+2,214
New +$82.3K 0.04% 116

Other funds holding VTGN

SFM
Sphera Funds Management Tel Aviv, Israel $630M AUM 108.65% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
II
Ibex Investors Denver, Colorado $152M AUM 19.17% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
LTFS
Ladenburg Thalmann Financial Services Miami, Florida $15.9B AUM 25.16% 1-Year Est. Return
DADC
D.A. Davidson & Co Great Falls, Montana $16.5B AUM 19.94% 1-Year Est. Return
Parallax Volatility Advisers
Parallax Volatility Advisers San Francisco, California $38.6B AUM 45.89% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
RC
RBF Capital San Francisco, California $2.05B AUM 29.64% 1-Year Est. Return
HighTower Advisors
HighTower Advisors Chicago, Illinois $94.2B AUM 21.24% 1-Year Est. Return

Corrado Advisors's VTGN Position: Q3 2018 in Review

Corrado Advisors sold out of VistaGen Therapeutics (VTGN) in Q3 2018, closing a stake of 1,514 shares — an estimated $62K sold.

Corrado Advisors first reported a position in VTGN in Q1 2018 and held it in 2 quarters. The position peaked at $62K in Q2 2018. 17 funds tracked by Wall St. Rank hold VTGN as of Q3 2018.

  • Corrado Advisors reported no remaining VistaGen Therapeutics position as of Q3 2018 after selling out during the quarter.
  • Corrado Advisors sold 1,514 VistaGen Therapeutics shares in Q3 2018, an estimated $62K.
  • Corrado Advisors first reported a position in VistaGen Therapeutics in Q1 2018 and held it in 2 quarters.
  • Corrado Advisors's VistaGen Therapeutics position peaked at $62K in Q2 2018.
  • 17 funds tracked by Wall St. Rank held VistaGen Therapeutics as of Q3 2018.

Based on Corrado Advisors's 13F filing for Q3 2018, filed 11 Oct 2018.